A view on drug resistance in cancer Review


Authors: Vasan, N.; Baselga, J.; Hyman, D. M.
Review Title: A view on drug resistance in cancer
Abstract: The problem of resistance to therapy in cancer is multifaceted. Here we take a reductionist approach to define and separate the key determinants of drug resistance, which include tumour burden and growth kinetics; tumour heterogeneity; physical barriers; the immune system and the microenvironment; undruggable cancer drivers; and the many consequences of applying therapeutic pressures. We propose four general solutions to drug resistance that are based on earlier detection of tumours permitting cancer interception; adaptive monitoring during therapy; the addition of novel drugs and improved pharmacological principles that result in deeper responses; and the identification of cancer cell dependencies by high-throughput synthetic lethality screens, integration of clinico-genomic data and computational modelling. These different approaches could eventually be synthesized for each tumour at any decision point and used to inform the choice of therapy. © 2019, Springer Nature Limited.
Keywords: cancer chemotherapy; gene mutation; review; cancer growth; antineoplastic agent; tumor volume; cancer screening; high throughput screening; drug resistance; cancer resistance; oncogene; tumor suppressor gene; early diagnosis; cancer cell; clinical decision making; drug monitoring; computer model; tumor microenvironment; tumor immunology; physical parameters; human; priority journal; malignant neoplasm
Journal Title: Nature
Volume: 575
Issue: 7782
ISSN: 0028-0836
Publisher: Nature Publishing Group  
Date Published: 2019-11-14
Start Page: 299
End Page: 309
Language: English
DOI: 10.1038/s41586-019-1730-1
PUBMED: 31723286
PROVIDER: scopus
PMCID: PMC8008476
DOI/URL:
Notes: Review -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. David Hyman
    354 Hyman
  2. Jose T Baselga
    484 Baselga
  3. Neil Vasan
    19 Vasan